{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-011895","form_type":"8-K","ticker":"PBSV","cik":"0001304161","company_name":"Pharma-Bio Serv, Inc.","filed_at":"2023-09-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.520629+00:00","generated_at":"2026-06-10T17:22:33.985077+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Pharma-Bio Serv Q3 net income up $0.2M to $0.5M; revenue down $0.2M to $4.6M","bullets":["Net income for Q3 FY2023 (three months ended July 31) was approx $0.5M, up from $0.3M YoY; nine-month net income $1.4M vs $0.9M.","Q3 revenue $4.6M, down from $4.8M YoY; nine-month revenue $13.4M vs $14.8M.","Gross profit margin improved 6.4 percentage points in Q3 and 5.3 percentage points YTD.","CEO Sanchez highlighted successful strategy, new market expansion, and leveraging FDA scrutiny for profitability."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-011895","json":"https://secwatch.observer/filing/0001654954-23-011895.json","markdown":"https://secwatch.observer/filing/0001654954-23-011895.md","text":"https://secwatch.observer/filing/0001654954-23-011895.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1304161/000165495423011895/0001654954-23-011895-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1304161/000165495423011895/pbsv_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T17:22:33.985077+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f96b95427f7d74ecd71adfa93a6b21d25e61c158","claim":"Pharma-Bio Serv, Inc. reported financial results for the three and nine months ended July 31, 2023.","evidence_excerpt":"On September 14, 2023, Pharma-Bio Serv, Inc. (the “Company”) issued a press release announcing its results of operations for the three and nine months ended July 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1304161/000165495423011895/0001654954-23-011895-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and nine months ended July 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}